skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Prevalence of Neuropathic Pain in Radiotherapy Oncology Units

Abstract

Purpose: Neuropathic pain (NP) in cancer patients severely impacts quality of life. Radiotherapy (RT) may cause NP, and at the same time, cancer patients visit RT units for pain relief. NP prevalence at these sites and current analgesic treatment should be assessed to improve management. Methods and Materials: This epidemiological, prospective, multicenter study was undertaken to assess NP prevalence, according to Douleur Neuropathique 4 questions questtionaire (DN4) test results, and analgesic management in cancer pain patients visiting RT oncologic units. Secondary analyses assessed NP etiology and pain intensity (using the Brief Pain Inventory-Short Form) and impact (using the Hospital Anxiety and Depression Scale (HADS), Medical Outcomes Study [MOS] for Sleep, and the Health Survey Short Form-12). Results: A total of 1,098 patients with any kind of pain were registered. NP prevalence was 31.1% (95% confidence interval, 28.4%--33.9%); 291 NP patients (mean age, 62.2 {+-}12.5 years and 57.7% men) were eligible for study; 49% of patients were overweight. The most frequent tumors were those of breast and lung, and stage IIIB was the most common cancer stage. The tumors caused 75% of NP cases. Anxiety, sleepiness, and depression were common. At 8 weeks, pain intensity and interference with daily activities decreasedmore » significantly for 50.8% of responders. Depression and anxiety (p < 0.0001) scores on the Physical Component Summary and Mental Component Summary measures (p < 0.0001) and all MOS-Sleep subscales, except for snoring, improved significantly. The percentage of satisfied patients increased from 13.8% to 87.4% (p < 0.0001) with the current analgesic treatment, which meant a 1.2- and 6-fold increase (p < 0.0001) in narcotic analgesics and anticonvulsants, respectively, compared to previous treatment. Conclusions: NP is highly prevalent at RT oncology units, with sleepiness, anxiety, and depression as frequent comorbidities. There is a need to improve management of NP with increased use of more specific NP-targeting drugs.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [5]
  1. Servicio de Oncologia Radioterapica, Hospital Universitario La Paz, Madrid (Spain)
  2. Servicio de Oncologia Radioterapica, Hospital Universitario de la Ribera, Valencia (Spain)
  3. Servicio de Oncologia Radioterapica, Hospital Txagorritxu, Vitoria-Alava (Spain)
  4. Servicio de Oncologia Radioterapica, Hospital de Torrecardenas, Almeria (Spain)
  5. Medical Unit, Pfizer Espana, Alcobendas (Spain)
  6. Department of Biometrics, European Biometrics Institute, Barcelona (Spain)
Publication Date:
OSTI Identifier:
21587741
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 81; Journal Issue: 2; Other Information: DOI: 10.1016/j.ijrobp.2010.05.047; PII: S0360-3016(10)00791-1; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANALGESICS; ANTICONVULSANTS; ETIOLOGY; LUNGS; MAMMARY GLANDS; NARCOTICS; NEOPLASMS; PAIN; RADIOTHERAPY; STANDARD OF LIVING; BODY; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DISEASES; DRUGS; GLANDS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RESPIRATORY SYSTEM; SYMPTOMS; THERAPY

Citation Formats

Manas, Ana, Monroy, Jose Luis, Ramos, Avelino Alia, Cano, Carmen, Lopez-Gomez, Vanessa, E-mail: Vanessa.LopezGomez@pfizer.com, Masramon, Xavier, and Perez, Maria. Prevalence of Neuropathic Pain in Radiotherapy Oncology Units. United States: N. p., 2011. Web. doi:10.1016/j.ijrobp.2010.05.047.
Manas, Ana, Monroy, Jose Luis, Ramos, Avelino Alia, Cano, Carmen, Lopez-Gomez, Vanessa, E-mail: Vanessa.LopezGomez@pfizer.com, Masramon, Xavier, & Perez, Maria. Prevalence of Neuropathic Pain in Radiotherapy Oncology Units. United States. doi:10.1016/j.ijrobp.2010.05.047.
Manas, Ana, Monroy, Jose Luis, Ramos, Avelino Alia, Cano, Carmen, Lopez-Gomez, Vanessa, E-mail: Vanessa.LopezGomez@pfizer.com, Masramon, Xavier, and Perez, Maria. Sat . "Prevalence of Neuropathic Pain in Radiotherapy Oncology Units". United States. doi:10.1016/j.ijrobp.2010.05.047.
@article{osti_21587741,
title = {Prevalence of Neuropathic Pain in Radiotherapy Oncology Units},
author = {Manas, Ana and Monroy, Jose Luis and Ramos, Avelino Alia and Cano, Carmen and Lopez-Gomez, Vanessa, E-mail: Vanessa.LopezGomez@pfizer.com and Masramon, Xavier and Perez, Maria},
abstractNote = {Purpose: Neuropathic pain (NP) in cancer patients severely impacts quality of life. Radiotherapy (RT) may cause NP, and at the same time, cancer patients visit RT units for pain relief. NP prevalence at these sites and current analgesic treatment should be assessed to improve management. Methods and Materials: This epidemiological, prospective, multicenter study was undertaken to assess NP prevalence, according to Douleur Neuropathique 4 questions questtionaire (DN4) test results, and analgesic management in cancer pain patients visiting RT oncologic units. Secondary analyses assessed NP etiology and pain intensity (using the Brief Pain Inventory-Short Form) and impact (using the Hospital Anxiety and Depression Scale (HADS), Medical Outcomes Study [MOS] for Sleep, and the Health Survey Short Form-12). Results: A total of 1,098 patients with any kind of pain were registered. NP prevalence was 31.1% (95% confidence interval, 28.4%--33.9%); 291 NP patients (mean age, 62.2 {+-}12.5 years and 57.7% men) were eligible for study; 49% of patients were overweight. The most frequent tumors were those of breast and lung, and stage IIIB was the most common cancer stage. The tumors caused 75% of NP cases. Anxiety, sleepiness, and depression were common. At 8 weeks, pain intensity and interference with daily activities decreased significantly for 50.8% of responders. Depression and anxiety (p < 0.0001) scores on the Physical Component Summary and Mental Component Summary measures (p < 0.0001) and all MOS-Sleep subscales, except for snoring, improved significantly. The percentage of satisfied patients increased from 13.8% to 87.4% (p < 0.0001) with the current analgesic treatment, which meant a 1.2- and 6-fold increase (p < 0.0001) in narcotic analgesics and anticonvulsants, respectively, compared to previous treatment. Conclusions: NP is highly prevalent at RT oncology units, with sleepiness, anxiety, and depression as frequent comorbidities. There is a need to improve management of NP with increased use of more specific NP-targeting drugs.},
doi = {10.1016/j.ijrobp.2010.05.047},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 2,
volume = 81,
place = {United States},
year = {2011},
month = {10}
}